Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | 4/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 3107 Cr | 8357 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.56% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 32 | 41 | ||
Top 5 Holdings | Cipla Ltd (9.16%) Sun Pharmaceuticals Industries Ltd (7.88%) Ipca Laboratories Ltd (7.56%) Cohance Lifesciences Ltd (7.38%) Laurus Labs Ltd (6.12%) | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (7.34%) Cipla Ltd (6.09%) Lupin Ltd (6.09%) Apollo Hospitals Enterprise Ltd (5.91%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.53%) Financial Services (1.47%) | Health (100%) | ||
Equity % | 97.14% | 99.48% | ||
Debt % | - | - | ||
P/E | 34.52 | 36.11 | ||
P/B | 5.13 | 5.78 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.31% | -0.19% | ||
3-Month Return | 3.43% | 0.64% | ||
6-Month Return | 10.82% | 12.17% | ||
1-Year Return | -0.81% | -0.52% | ||
3-Year Return | 26.57% | 25% | ||
5-Year Return | 19.51% | 19.15% |
Sharpe | 1.22 | 1.06 | ||
Alpha | 3.64 | 0.66 | ||
Beta | 0.84 | 0.91 | ||
Standard Deviation | 14.59 | 15.05 | ||
Information Ratio | 0.23 | -0.24 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Sailesh Raj Bhan,Kinjal Desai |